SiBone (NASDAQ:SIBN) SVP Sells $67,885.20 in Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,460 shares of SiBone stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $19.62, for a total transaction of $67,885.20. Following the sale, the senior vice president owned 228,436 shares of the company’s stock, valued at $4,481,914.32. The trade was a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

SiBone Stock Performance

Shares of SIBN stock opened at $20.88 on Friday. The business has a fifty day moving average of $18.82 and a 200 day moving average of $17.09. SiBone has a 1 year low of $12.49 and a 1 year high of $21.89. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62. The firm has a market capitalization of $906.00 million, a price-to-earnings ratio of -40.94 and a beta of 0.69.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The business had revenue of $48.66 million for the quarter, compared to analyst estimates of $46.67 million. As a group, research analysts expect that SiBone will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On SiBone

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue acquired a new stake in shares of SiBone in the third quarter valued at about $39,000. State of Wyoming purchased a new position in SiBone in the 2nd quarter valued at about $55,000. Canada Pension Plan Investment Board acquired a new stake in SiBone in the 2nd quarter worth about $68,000. Quarry LP boosted its holdings in SiBone by 862.6% in the 3rd quarter. Quarry LP now owns 4,861 shares of the company’s stock worth $72,000 after buying an additional 4,356 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in SiBone by 198.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,897 shares of the company’s stock worth $92,000 after buying an additional 3,258 shares in the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SIBN has been the subject of a number of recent research reports. Truist Financial lifted their price objective on SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Needham & Company LLC raised their price target on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Morgan Stanley lifted their price objective on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, Canaccord Genuity Group upped their price objective on shares of SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, SiBone currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.